Navigation Links
Pathwork Diagnostics Announces Key Additions to Management Team
Date:10/8/2008

CFO and VP of US Sales Bring Industry Expertise to Pathwork Following FDA

Clearance and $20M Fundraising Round

SUNNYVALE, Calif., Oct. 8 /PRNewswire/ -- Pathwork Diagnostics, a molecular diagnostics company focused on oncology, announced today the appointment of two key positions within the company's management team, Fletcher Payne as Chief Financial Officer and Mark McDonough as Vice President of US Sales. These professionals bring over 20 years of industry expertise in their respective positions to Pathwork.

"Having Fletcher and Mark on the Pathwork management team will be a great asset moving forward," said Deborah J. Neff, President and Chief Executive Officer of Pathwork Diagnostics. "Both have proven track records in helping emerging companies grow efficiently and achieve results."

Pathwork's new CFO, Fletcher Payne, a graduate of UC Berkeley's Haas School of Business with a BS in Business Administration, joins Pathwork from Plexxikon Inc., a biopharmaceutical company where he served as a VP and CFO. Payne will lead the financial team, implement processes to support commercial growth and develop the overall financial strategy. Payne has over 20 years of business and financial experience, in both start-up and Fortune 500 companies. Prior to Plexxikon, he worked for Rinat Neuroscience, Dynavax Technologies, Cell Genesys, Sun Microsystems and IBM.

Mark McDonough joins Pathwork as Vice President of US Sales from US LABS, a division of Laboratory Corporation of America. With over 10 years of cancer diagnostics and reference laboratory experience, Mark will be responsible for the strategic and tactical sales initiatives at Pathwork. Prior to his time at US LABS, McDonough held various sales and sales management roles at Ventana Medical Systems and served as a Navigator and Communications Officer in the United States Navy. McDonough is a graduate of Miami University of Ohio with a BS in Finance.

About Pathwork Diagnostics

Pathwork Diagnostics, Inc., based in Sunnyvale, Calif., develops and commercializes high-value molecular diagnostics for oncology. The company's first test to market -- the Pathwork(R) Tissue of Origin Test -- utilizes proprietary analytics and a companion Pathchip(R) microarray, which runs on the proven Affymetrix GeneChip(R) System. The test aids in determining a hard-to-identify tumor's origin so that standard-of-care, cancer-specific treatment can begin. The test is FDA-cleared as an in vitro diagnostic kit, while a functionally equivalent version of the test is also available through the CLIA-certified Pathwork(R) Diagnostics Laboratory. For more information, call 1.877.808.0006 or visit http://www.pathworkdx.com.

Pathwork, Pathchip, Pathwork Diagnostics, and the Pathwork Diagnostics logo are trademarks or registered trademarks of Pathwork Diagnostics, Inc. Other names may be the trademarks of their respective owners.


'/>"/>
SOURCE Pathwork Diagnostics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pathwork Diagnostics Closes $20M Financing
2. Pathwork(R) Diagnostics Launches Genomics-Based Test For Hard-To-Identify Tumors Through Its CLIA-Certified Laboratory
3. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
4. InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List
5. Fujirebio Diagnostics Named One of the Best Places to Work in Pennsylvania
6. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
7. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
8. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
9. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
10. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
11. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
(Date:6/22/2016)... DUBLIN , June 22, 2016 Research ... and Global Markets" report to their offering. ... $39.4 billion in 2014 from $29.3 billion in 2013. The market ... (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion ... and projected product forecasts during the forecast period (2015 to 2020) ...
Breaking Biology Technology:
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):